Quantitative UHF-ECG Assessment of Pacing-Induced Ventricular Activation: Comparison of LBBAP and RV Septal Pacing.

Pacing Clin ElectrophysiolMay 7, 2026 (epub)
Case ReportCardiology

Talgat K Yessenov, Telman Z Seisembekov, Ayan Nurkesh et al.

✦ AI-curated · Sources linked

Case in brief

This report describes two patients with bradycardia who underwent dual-chamber pacemaker implantation, one receiving left bundle branch area pacing (LBBAP) and the other right ventricular septal pacing (RVSP). UHF-ECG analysis revealed that the LBBAP case maintained low dyssynchrony with minimal changes in QRS duration and ventricular activation indices, while the RVSP case exhibited significant increases in dyssynchrony metrics.

Diagnostic / clinical pearl

UHF-ECG can quantitatively assess ventricular activation synchrony, distinguishing between LBBAP and RVSP, which may have implications for pacing strategy in bradycardia patients.

Why it matters

Understanding the differences in ventricular activation patterns between pacing techniques can guide clinicians in optimizing pacing strategies for better patient outcomes.

Source

PubMed · PMID 42099084

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.